MiMedx

471 articles about MiMedx

• MIMEDX Announces First Quarter 2022 Operating and Financial Results

  5/3/2022

  MiMedx Group, Inc., a transformational placental biologics company, announced the filing of its first quarter 2022 Form 10-Q for the period ended March 31, 2022.

• MIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4

  4/20/2022

  MiMedx Group, Inc. today announced that it will report operating and financial results for the first quarter ended March 31, 2022 after the market close on Tuesday, May 3, 2022.

• MIMEDX to Present Health Economics Clinical Data for EPIFIX® in Treatment of Lower Extremity Diabetic Ulcers at SAWC Spring

  4/5/2022

  MiMedx Group, Inc., a transformational placental biologics company, announced it will sponsor a lunch symposium at the Symposium on Advanced Wound Care Spring on April 6-10 in Phoenix, Arizona.

• WoundGenex Partners with MIMEDX to Launch Premier Graft Program to Wound Care Providers Nationwide

  3/16/2022

  Leading wound care management and clinical services provider, WoundGenex, announced a strategic partnership with MiMedx Group, Inc., a transformational placental biologics company, to launch an exclusive version of WoundGenex's Premier Graft Program to its clients across the country, providing clinicians access to industry-leading allograft products through a convenient purchasing option.

• MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

  2/28/2022

  MiMedx Group, Inc., a transformational placental biologics company, announced the filing of its 2021 Annual Report on Form 10-K for the year ended December 31, 2021.

• MIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28

  2/14/2022

  MiMedx Group, Inc., a transformational placental biologics company, announced that it will report operating and financial results for the fourth quarter ended December 31, 2021 after the market close on Monday, February 28, 2022.

• MIMEDX Outlines Key Strategic Milestones for 2022

  1/10/2022

  MiMedx Group, Inc., a transformational placental biologics company, provided a recap of key 2021 accomplishments and outlined strategic milestones planned for 2022.

• MIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference

  1/4/2022

  MiMedx Group, Inc. announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.

• MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference

  12/22/2021

  MiMedx Group, Inc. today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present during the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12 at 5:15 PM EST.

• MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day

  12/7/2021

  MiMedx Group, Inc., a transformational placental biologics company, will provide new details about near- and long-term growth opportunities for its multimodal placental tissue platform at ’s virtual Investor Day, which begins at 9:00 a.m. ET.

• MIMEDX Announces Speakers for December 7 Investor Day

  11/30/2021

  Company to Host Virtual Event on December 7, 2021 Beginning at 9:00 a.m. ET.

• MIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference

  11/22/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that Timothy R. Wright, Chief Executive Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will present at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 to December 2, 2021.

• MIMEDX to Participate at Upcoming Investor Conferences - Nov 02, 2021

  11/2/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Rohit Kashyap, Ph.D., Chief Commercial Officer, will be participating in the following virtual investor conferences:.

• MIMEDX Announces Third Quarter 2021 Operating and Financial Results

  11/2/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced the filing of its third quarter 2021 Form 10-Q for the period ended September 30, 2021.

• MIMEDX to Host Virtual Investor Day on December 7, 2021

  10/14/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced that it will host a virtual Investor Day on Tuesday, December 7, 2021 beginning at 9:00 a.m. ET.

• 

  Clinical Catch-Up: September 13-17

  9/20/2021

  With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.

• MIMEDX Announces Effectiveness of Shelf Registration Statement

  9/8/2021

  MiMedx Group, Inc. today announced the shelf registration statement on Form S-3 on file with the Securities and Exchange Commission (SEC) has become effective.

• MIMEDX to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/7/2021

  MiMedx Group, Inc. today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will present at the H.C. Wainwright 23rd Annual Global Investment Conference held on September 13 - 15, 2021.

• MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs

  8/12/2021

  MiMedx Group, Inc. today announced the promotion of Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs.

• MIMEDX Announces Second Quarter 2021 Operating and Financial Results

  8/3/2021

  MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced the filing of its second quarter 2021 Form 10-Q for the period ended June 30, 2021.